Optain company profile
Optain is working to make retinal screening simple, accessible, and standard in frontline care. Diabetic retinopathy is a leading cause of blindness, yet preventable and treatable with routine screening. The barrier has never been the science - it's fit. Screening tools built for specialists were never designed to fit the reality of primary care.…
About Optain
Optain is working to make retinal screening simple, accessible, and standard in frontline care. Diabetic retinopathy is a leading cause of blindness, yet preventable and treatable with routine screening. The barrier has never been the science - it's fit. Screening tools built for specialists were never designed to fit the reality of primary care. Optain provides a complete end-to-end solution - from image capture to AI/teleophthalmology-based grading* and reporting, designed to fit within a scheduled primary care visit, driving measurable clinical impact and ROI. Optain was founded in 2023, building on more than a decade of Australian AI-ophthalmology research led by Professor Mingguang He, and operates across frontline care globally. *AI-based grading: not currently available in the US and certain markets. Teleophthalmology: currently US only. Contact us for details.
Mission and direction
Optain develops an end-to-end retinal screening platform that makes eye disease detection simple, accessible, and practical for frontline care. Combining fundus imaging hardware, AI-assisted grading, teleophthalmology, and clinical expertise, the company helps healthcare providers integrate high-quality screening into routine workflows to improve patient outcomes and support broader access to preventive care.
Company values
- Accessibility
- Clinical impact
- Innovation
- Collaboration
- Patient outcomes